Outpatient Oncology Infusion Market Analysis, Demand, Challenges and Future Opportunities 2034
Outpatient Oncology Infusion Market Growth, Size, Trends Analysis - By Product, By Application, By Therapy, By Mode - Regional Outlook, Competitive Strategies and Segment Forecast to 2034
| Published: Mar-2025 | Report ID: HLCA2582 | Pages: 1 - 260 | Formats*: |
| Category : Healthcare | |||
Outpatient Oncology Infusion Market Introduction and Overview
According to SPER Market Research, the Global Outpatient Oncology Infusion Market is estimated to reach USD 7.46 billion by 2034 with a CAGR of 10.86%.
The report includes an in-depth analysis of the Global Outpatient Oncology Infusion Market, including market size and trends, product mix, Applications, and supplier analysis. The market for outpatient oncology infusions is expanding as cancer treatment moves from inpatient to outpatient settings due to patient convenience and cost-effectiveness. By offering targeted therapies, immunotherapy, and chemotherapy, outpatient infusion clinics lessen the strain on hospitals while maintaining ongoing care. Rising cancer rates, improvements in biologics, and growing demand for value-based healthcare are some of the main motivators. The market is also growing as a result of improved insurance coverage and favourable government regulations. The requirement for specialist staffing, complicated reimbursement procedures, and exorbitant drug costs, however, make development difficult. Barriers include issues with patient safety and infrastructure constraints. Personalized medicine and infusion technology advancements are anticipated to improve market accessibility and efficiency.
By Product Insights: Outpatient Oncology Infusion is classified into four categories based on Product: Infusion pumps, Intravenous sets, IV cannulas, Needleless connectors. The segment that produced the most revenue was infusion pumps. Because of their improved patient outcomes, ability to administer complex chemotherapy regimens, and precision in drug delivery, IV infusion pumps are becoming more and more popular for cancer therapies at outpatient clinics. Additionally, chemotherapeutic medicines can be continuously and precisely delivered via infusion pumps, which lowers dosing errors and improves treatment effectiveness.
By Application Insights: The market for Outpatient Oncology Infusion is segmented based on Applications, including Lung cancer, Liver cancer, Breast cancer and Prostate cancer. The market was dominated by the breast cancer category. The increasing global incidence of breast cancer, the variety and sophistication of available treatments, the preference of patients for outpatient care, supportive care services, and patient education and support initiatives are all factors contributing to the growth of this market. Early detection is also a result of the extensive and successful breast cancer screening programs.
By Therapy Insights: The market for Outpatient Oncology Infusion is segmented based on Therapy, including Chemotherapy, Targeted therapy, Immunotherapy, Hormonal therapy. The market was controlled by the targeted therapy category. Based on the genetic composition of a patient's tumour, targeted therapies such as small molecule inhibitors and monoclonal antibodies offer individualized therapy options. When compared to conventional chemotherapy, this accuracy results in increased efficacy and fewer adverse effects. Furthermore, developments in molecular diagnostics have made it easier to pinpoint particular targets, which has improved the creation and use of these treatments.
By Mode Insights: The market for Outpatient Oncology Infusion is segmented based on Mode, including Intramuscular (IM), Intravenous (IV) and Subcutaneous. Market dominance was held by the intravenous (IV) segment. Through intravenous injection, chemotherapy and other therapeutic substances can be directly delivered into the bloodstream, guaranteeing quick and regulated absorption. The number of medical facilities offering IV treatments for cancer has also significantly increased, which is anticipated to promote segment expansion. IV modalities are becoming more and more popular as a result of the development in targeted medicines, which frequently call for IV administration.
By Regional Insights: The market for outpatient oncology infusions is led by North America because to its sophisticated healthcare system, high cancer incidence, and emphasis on innovation. This supremacy is further supported by the region's emphasis on early diagnosis and all-encompassing treatment options. The broad use of outpatient infusion services is also facilitated by strong reimbursement structures and encouraging government regulations.
Market Competitive Landscape:
There are a number of significant participants in the market, and technological innovation and strategic alliances are prioritized. To introduce sophisticated and clever infusion pumps and related equipment, these companies make large investments in research and development. Some of the key market players are B. Braun Melsungen AG, Baxter, Becton, Dickinson, and Company, Fresenius Kabi, ICU Medical, Inc, IRadimed Corporation, Medtronic PLC, Micrel Medical Devices SA, Moog, Inc. and Nipro Corporation.
Recent Developments:
- In November 2024, According to Merck, a study revealed that the injectable form of their cancer medication Keytruda is not inferior compared to the current intravenous (IV) formulation. This discovery may improve accessibility while streamlining administration. In the world, Keytruda is the most famous medication.
- In September 2024, Major U.S. drug wholesalers, like as McKesson, Cencora, and Cardinal Health, have been purchasing oncology clinics for the purpose to lock in clients and strengthen their market positions, based to a Wall Street Journal investigation.
- In March 2024, The HCG Care app was launched for cancer patients by HealthCare Global Enterprises Ltd. in Bangalore, India. The app offers all of the digital cancer care services on a single dashboard.
Scope of the Report:
| Report Metric | Details |
| Market size available for years | 2021-2034 |
| Base year considered | 2024 |
| Forecast period | 2025-2034 |
| Segments covered | By Product, By Application, By Therapy, By Mode. |
| Regions covered | North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa. |
| Companies Covered | B. Braun Melsungen AG, Baxter, Becton, Dickinson, and Company, Fresenius Kabi, ICU Medical, Inc, IRadimed Corporation, Medtronic PLC, Micrel Medical Devices SA, Moog, Inc., Nipro Corporation. and others. |
Key Topics Covered in the Report:
- Global Outpatient Oncology Infusion Market Size (FY’2021-FY’2034)
- Overview of Global Outpatient Oncology Infusion Market
- Segmentation of Global Outpatient Oncology Infusion Market By Product (Infusion pumps, Intravenous sets, IV cannulas, Needleless connectors)
- Segmentation of Global Outpatient Oncology Infusion Market By Application (Lung cancer, Liver cancer, Breast cancer, Prostate cancer)
- Segmentation of Global Outpatient Oncology Infusion Market By Therapy (Chemotherapy, Targeted therapy, Immunotherapy, Hormonal therapy)
- Segmentation of Global Outpatient Oncology Infusion Market By Mode (Intramuscular (IM), Intravenous (IV), Subcutaneous)
- Statistical Snap of Global Outpatient Oncology Infusion Market
- Expansion Analysis of Global Outpatient Oncology Infusion Market
- Problems and Obstacles in Global Outpatient Oncology Infusion Market
- Competitive Landscape in the Global Outpatient Oncology Infusion Market
- Details on Current Investment in Global Outpatient Oncology Infusion Market
- Competitive Analysis of Global Outpatient Oncology Infusion Market
- Prominent Players in the Global Outpatient Oncology Infusion Market
- SWOT Analysis of Global Outpatient Oncology Infusion Market
- Global Outpatient Oncology Infusion Market Future Outlook and Projections (FY’2025-FY’2034)
- Recommendations from Analyst
1. Introduction
1.1. Scope of the report1.2. Market segment analysis
2. Research Methodology
2.1. Research data source
2.1.1. Secondary Data2.1.2. Primary Data2.1.3. SPERs internal database2.1.4. Premium insight from KOLs
2.2. Market size estimation
2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1. Drivers4.1.2. Restraints4.1.3. Opportunities4.1.4. Challenges
5. Market variable and outlook
5.1. SWOT Analysis
5.1.1. Strengths5.1.2. Weaknesses5.1.3. Opportunities5.1.4. Threats
5.2. PESTEL Analysis
5.2.1. Political Landscape5.2.2. Economic Landscape5.2.3. Social Landscape5.2.4. Technological Landscape5.2.5. Environmental Landscape5.2.6. Legal Landscape
5.3. PORTERs Five Forces
5.3.1. Bargaining power of suppliers5.3.2. Bargaining power of buyers5.3.3. Threat of Substitute5.3.4. Threat of new entrant5.3.5. Competitive rivalry
5.4. Heat Map Analysis
6. Competitive Landscape
6.1. Global Outpatient Oncology Infusion Market Manufacturing Base Distribution, Sales Area, Product Type6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Outpatient Oncology Infusion Market
7. Global Outpatient Oncology Infusion Market, By Product (USD Million) 2021-2034
7.1. Infusion pumps7.2. Intravenous sets7.3. IV cannulas7.4. Needleless connectors
8. Global Outpatient Oncology Infusion Market, By Application (USD Million) 2021-2034
8.1. Lung cancer8.2. Liver cancer8.3. Breast cancer8.4. Prostate cancer
9. Global Outpatient Oncology Infusion Market, By Therapy (USD Million) 2021-2034
9.1. Chemotherapy9.2. Targeted therapy9.3. Immunotherapy9.4. Hormonal therapy
10. Global Outpatient Oncology Infusion Market, By Mode (USD Million) 2021-2034
10.1. Intramuscular (IM)10.2. Intravenous (IV)10.3. Subcutaneous
11. Global Outpatient Oncology Infusion Market, (USD Million) 2021-2034
11.1. Global Outpatient Oncology Infusion Market Size and Market Share
12. Global Outpatient Oncology Infusion Market, By Region, (USD Million) 2021-2034
12.1. Asia-Pacific
12.1.1. Australia12.1.2. China12.1.3. India12.1.4. Japan12.1.5. South Korea12.1.6. Rest of Asia-Pacific
12.2. Europe
12.2.1. France12.2.2. Germany12.2.3. Italy12.2.4. Spain12.2.5. United Kingdom12.2.6. Rest of Europe
12.3. Middle East and Africa
12.3.1. Kingdom of Saudi Arabia12.3.2. United Arab Emirates12.3.3. Qatar12.3.4. South Africa12.3.5. Egypt12.3.6. Morocco12.3.7. Nigeria12.3.8. Rest of Middle-East and Africa
12.4. North America
12.4.1. Canada12.4.2. Mexico12.4.3. United States
12.5. Latin America
12.5.1. Argentina12.5.2. Brazil12.5.3. Rest of Latin America
13. Company Profile
13.1. B. Braun Melsungen AG
13.1.1. Company details13.1.2. Financial outlook13.1.3. Product summary13.1.4. Recent developments
13.2. Baxter
13.2.1. Company details13.2.2. Financial outlook13.2.3. Product summary13.2.4. Recent developments
13.3. Becton, Dickinson, and Company
13.3.1. Company details13.3.2. Financial outlook13.3.3. Product summary13.3.4. Recent developments
13.4. Fresenius Kabi
13.4.1. Company details13.4.2. Financial outlook13.4.3. Product summary13.4.4. Recent developments
13.5. ICU Medical, Inc
13.5.1. Company details13.5.2. Financial outlook13.5.3. Product summary13.5.4. Recent developments
13.6. IRadimed Corporation
13.6.1. Company details13.6.2. Financial outlook13.6.3. Product summary13.6.4. Recent developments
13.7. Medtronic PLC
13.7.1. Company details13.7.2. Financial outlook13.7.3. Product summary13.7.4. Recent developments
13.8. Micrel Medical Devices SA
13.8.1. Company details13.8.2. Financial outlook13.8.3. Product summary13.8.4. Recent developments
13.9. Moog, Inc.
13.9.1. Company details13.9.2. Financial outlook13.9.3. Product summary13.9.4. Recent developments
13.10. Nipro Corporation
13.10.1. Company details13.10.2. Financial outlook13.10.3. Product summary13.10.4. Recent developments
13.11. Others
14. Conclusion
15. List of Abbreviations
16. Reference Links
SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.
The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.
Frequently Asked Questions About This Report
The market for outpatient oncology infusions is expanding as cancer treatment moves from inpatient to outpatient settings due to patient convenience and cost-effectiveness. By offering targeted therapies, immunotherapy, and chemotherapy, outpatient infusion clinics lessen the strain on hospitals while maintaining ongoing care.
Outpatient Oncology Infusion Market is projected to reach USD 7.46 billion by 2034, growing at a CAGR of 10.86% during the forecast period.
Outpatient Oncology Infusion Market grew in Market size from 2025. The Market is expected to reach USD 7.46 billion by 2034, at a CAGR of 10.86% during the forecast period.
Outpatient Oncology Infusion Market CAGR of 10.86% during the forecast period.
You can get the sample pages by clicking the link - Click Here
Outpatient Oncology Infusion Market size is USD 7.46 billion from 2025 to 2034.
Outpatient Oncology Infusion Market is covered By Product, By Application, By Therapy, By Mode.
The North America is anticipated to have the highest Market share in the Outpatient Oncology Infusion Market.
"The key players in the Market include Companies Covered B. Braun Melsungen AG, Baxter, Becton, Dickinson, and Company, Fresenius Kabi, ICU Medical, Inc, IRadimed Corporation, Medtronic PLC, Micrel Medical Devices SA, Moog, Inc., Nipro Corporation. and others.
PLACE AN ORDER
Year End Discount
Sample Report
Pre-Purchase Inquiry
NEED CUSTOMIZATION?
Request CustomizationCALL OR EMAIL US
100% Secure Payment
Related Reports
Have a glance of the Report
Our Global Clients
Our data-driven insights have influenced the strategy of 200+ reputed companies across the globe.
